Wednesday 28th September 2016

Nintedanib Receives Orphan Drug Designation for Systemic Sclerosis

The FDA has granted Orphan Drug Designation to Boehringer Ingelheim’s nintedanib for the treatment of systemic sclerosis (SSc), also known as scleroderma, including associated interstitial lung disease (SSc-ILD). - See more at: http://www.pharmacytimes.com/product-news/nintedanib-receives-orphan-drug-designation-for-systemic-sclerosis#sthash.5ACj39Ga.dpuf

Read Article

Wednesday 14th September 2016

Edgar Stene Prize Competition 2017 launched

The Edgar Stene Prize Competition 2017 is for people with rheumatic and musculoskeletal diseases (RMDs) to write about their personal experience and submit an essay by 31st December 2016. Launched by National organisations of people with arthritis/rheumatism (EULAR) and across Europe (PARE).

Read Article

Monday 5th September 2016

SRUK First Annual Conference

Our first ever Annual Conference was held in August 2016 and was a great success. It brought together key industry leaders and medical professionals to present on the latest research, methods of diagnosis, treatments and managing the condition.

Read Article

Monday 5th September 2016

Fantastic community event in Nottingham

Nottingham local councillor Corall Jenkins recently held a brilliant community event in memory of her husband Stan, who sadly passed away from scleroderma.

Read Article

Sunday 4th September 2016

Scleroderma Clinical Research Study Enrolment

This information is intended for residents of the UK Now Enroling Patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc) also called Scleroderma Have you or someone you know been diagnosed with diffuse cutaneous systemic sclerosis? Would you/they be interested in participating in a clinical research study?

Read Article

Thursday 25th August 2016

Finding strength in numbers

“Strength in numbers”: an oft used phrase, but like many such clichés it has evolved to mean different things to different people. For me, as Chief Executive of Scleroderma & Raynaud's UK (SRUK), the only UK Charity dedicated to improving the lives of people with these debilitating autoimmune conditions, ‘strength in numbers’ has multiple meanings. Read Sue Farrington's interview with National Voices.

Read Article

Friday 22nd July 2016

Increasing Awareness

During June we launched our first public facing awareness campaign to highlight the signs and symptoms of Raynaud’s and the link between Raynaud’s and Scleroderma.

Read Article

Thursday 21st July 2016

Charity Spotlight - OpenCity Inc

Thank you to OPENCITY INC for featuring us this month in their Charity Spotlight. Take a read of the article John Gregory wrote about SRUK.

Read Article

Wednesday 6th July 2016

Afternoon Tea

Yun Wah Wan organised this amazing afternoon tea in celebration of the merger between the Scleroderma Society and Raynaud's and Scleroderma Association to for SRUK.

Read Article

Monday 13th June 2016

The BSR/BHPR Guideline for Scleroderma - what does it mean for patients?

Over the past 2 years an intensive amount of work has been undertaken to develop the first national UK guideline for treatment of scleroderma. This has been a group effort performed on behalf of the BSR (British Society of Rheumatology) and BHPR (British Health Professionals in Rheumatology) to develop an expert driven evidence based series of recommendations for the management of scleroderma.

Read Article